Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AVDL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Market Cap
Shares Outstanding
Share in Float
Dividende
Earning Date
No Data
Price Target
Average Volume
Beta
Range
Industry
Website
Sector
Earnings Growth
YoY
Current
Estimates
Sales Growth
YoY
Current
Estimates
Return on Equity
QoQ
Institutionnal Ownership
QoQ
Q3.23
N/A
-0.41
vs -0.33
Q4.23
N/A
-0.32
vs -0.44
Q1.24
N/A
-0.30
vs -0.48
Q2.24
N/A
-0.14
vs -0.70
Q3.24
N/A
-0.03
vs -0.41
Q4.24
N/A
-0.05
vs -0.32
Q1.25
N/A
-0.05
vs -0.30
Q2.25
N/A
NA
vs -0.14
Q3.25
+324%
0.07
vs -0.03
Q4.25
+314%
0.11
vs -0.05
Q3.23
NA
7M vs NA
Q4.23
NA
19.5M vs NA
Q1.24
NA
27.2M vs NA
Q2.24
+2674%
41.5M vs 1.5M
Q3.24
+613%
50M vs 7M
Q4.24
+159%
50.4M vs 19.5M
Q1.25
+93%
52.5M vs 27.2M
Q2.25
+64%
68.1M vs 41.5M
Q3.25
+47%
73.7M vs 50M
Q4.25
+56%
78.7M vs 50.4M
Q1.23
+81%
0.81
vs 1.3
Q2.23
-45%
-0.45
vs 0.81
Q3.23
-33%
-0.33
vs -0.45
Q4.23
-33%
-0.33
vs -0.33
Q1.24
-35%
-0.35
vs -0.33
Q2.24
-20%
-0.20
vs -0.35
Q3.24
-4%
-0.04
vs -0.20
Q4.24
-7%
-0.07
vs -0.04
Q1.25
-7%
-0.07
vs -0.07
Q2.25
+11%
0.11
vs -0.07
Q1.23
100
100
vs 97
3%
Q2.23
111
111
vs 100
11%
Q3.23
109
109
vs 111
-2%
Q4.23
122
122
vs 109
12%
Q1.24
132
132
vs 122
8%
Q2.24
170
170
vs 132
29%
Q3.24
198
198
vs 170
16%
Q4.24
175
175
vs 198
-12%
Q1.25
186
186
vs 175
6%
Q2.25
173
173
vs 186
-7%
seekingalpha.com
1 hour ago
globenewswire.com
7 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Forecast
422%2026-Revenue
707%2026-EPS
-251%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Rodman & Renshaw
initialisePrevious: Not converted
2024-06-11
Now: Buy
Jefferies
downgradePrevious: Not converted
2022-08-09
Now: Buy
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.57Â ( 4.00%)
Pre-market 14.98$0.16 (1.08%)
Relative Strenght
87
Volume Buzz
18%
Earning Acce
Yes
Dist 52w H.
11%Relative Strength
AVDL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|